Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

43.66 +2.55 (+6.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Coronavirus Cases Are on the Rise -- Should You Buy Vaccine Stocks?
Investors have worried about vaccine revenue in a post-pandemic world. 
Via The Motley Fool
Exposures COVID-19
3 Beaten-Down Biotech Stocks Bound for a Bounce Back
Biotech stocks are still below their post-pandemic peaks. But these beaten-down biotech stocks could lead the sector to new highs. 
Via InvestorPlace
Surprise! This Potential AI Winner Isn't a Tech Stock.
I'll give you a hint: You've probably heard of this company's big product. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Here's Why the Next 4 Months May Be Critical for Pfizer
The pharmaceutical giant's stock has dropped by around 30% year to date. 
Via The Motley Fool
What's Going On With Moderna (MRNA) Stock?
Moderna Inc (NASDAQ: MRNA) shares are trading lower by 2.4% to $113.80 Thursday afternoon. The stock has seen volatility in recent sessions amid rising COVID-19 cases in the U.S. 
Via Benzinga
Exposures COVID-19
Moderna Unusual Options Activity For August 31
Via Benzinga
Moderna to Host Investor Event - R&D Day and Business Updates
Via ACCESSWIRE
Moderna Unusual Options Activity
Via Benzinga
Check Out What Whales Are Doing With MRNA
Via Benzinga
Moderna Inc. (NASDAQ: MRNA) Highlighted for Surprising Price Action
Via Investor Brand Network
Beaten Down COVID-19 Vaccine Partner Stock Catalent Finalizes Deal With Activist Investor, Reports Mixed Q4 Earnings
Catalent Inc (NYSE: CTLT), valued at around $8 billion, has finalized a deal with activist investor Elliott Investment Management.  
Via Benzinga
Exposures COVID-19
Why Novavax Stock Was So Healthy on Monday
As the coronavirus threat rises, so too does the vaccine maker's value to investors. 
Via The Motley Fool
Exposures COVID-19
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
What's Going On With Moderna Stock Monday?
Moderna Inc (NASDAQ: MRNA) shares are trading higher by roughly 2% to $114.12 Monday morning. The stock is rising amid rising COVID-19 cases in the U.S. 
Via Benzinga
Exposures COVID-19
More Trouble Ahead For Bulls? Prepare For The Busy Upcoming Week With Mando Trading!
Jackson Hole Week comes to a close with a pretty ugly weekly candle. With DXY still strong, it's pretty hard for me to be bullish on the higher time frame right now. That weekly volume imbalance just... 
Via Benzinga
Ross Stores, Vertex Pharmaceuticals And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed higher on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca
China’s drug distributors are in the hunt to acquire Poland’s Neuca, a company with a 32% market share of Poland’s pharmaceutical distribution business. The consortium of China’s drug distributors may... 
Via Talk Markets
Is Alexandria Real Estate Equities a Buy?
Great company, attractive valuation, lousy sector. 
Via The Motley Fool
Market Rally Attempt Suffers Big Reversal Amid Nvidia Earnings, Powell Speech: Weekly Review
A rally attempt gained momentum, until Thursday's ugly reversal. 
Via Investor's Business Daily
7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot Pole
There are some solid biotech stocks on the market. But there are many more that deserve an “F” rating from the Portfolio Grader. 
Via InvestorPlace
Novavax (NVAX) Stock Is Getting Ready to Rally Again
Novavax only has an Emergency Use Authorization and faces a struggle to get paid for its protein-based Covid shot. 
Via InvestorPlace
Exposures COVID-19
Tuesday Talk: Monday Rebound
On Monday, the market rallied to rebound higher after a tough week of sideways and downward action. It remains to be seen if the rebound will be sustainable. 
Via Talk Markets
Nvidia, Zoom, Moderna, Baidu, Tesla: Why These Five Stocks Are Drawing Investors' Attention Today
Via Benzinga
Why Moderna, BioNTech SE, and Novavax Surged Today
The companies have developed vaccines for the current dominant strain of COVID, and the Biden administration is getting behind a new booster campaign. 
Via The Motley Fool
Exposures COVID-19
S&P 500: Cybersecurity Giant Soars On Earnings; Tesla, Nvidia Are Big Winners
Palo Alto surged on earnings. Tesla and NVDA were big winners too. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Crude Oil Falls; Nikola Shares Plummet
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 1.5% on Monday. The Dow traded down 0.16% to 34,446.91 while the NASDAQ rose 1.52% to 13,492.73. The S&P... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) shares jumped 120% to $0.33. 
Via Benzinga
Dow Tumbles Over 100 Points; Timber Pharmaceuticals Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 100 points on Monday. The Dow traded down 0.40% to 34,362.93 while the NASDAQ rose 0.78% to 13,394.60. The S&P 500,... 
Via Benzinga
Topics Stocks
Exposures US Equities
Moderna Surges On A Second, Unexpected Shot At The Cancer Vaccine Market
The company inked a new deal on Monday to test a new regimen using a second cancer vaccine. 
Via Investor's Business Daily
Moderna Teams Up With Chinese Biotech To Assess Cell-Based Therapy And Cancer Vaccine Combo
A Chinese biotech, CARsgen Therapeutics and Moderna Inc (NASDAQ: MRNA) have collaborated 
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.